What to Know About JIDEYTRO upcoming Webinar.

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC GSK's first approval in lung cancer, part of a growing portfolio of targeted treatments GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor,...

A Message of Hope and Progress Although treatment decisions for ROS1-positive (ROS1+) cancer can feel complicated, there is real reason for hope. In recent years, care has changed dramatically. Not long ago, there were no targeted treatments for ROS1, and today there are multiple approved options, with more new therapies being developed and studied. This progress means that if something changes—whether it’s side effects or the cancer growing again—it is not the end of the road. Instead, it...